Uljani ekstrakt račića Antarktika sa dodatkom polikozanola i koenzima Q10
Inpharm Co. d.o.o
Batajnički drum 23, 11080 Beograd - Zemun Srbija
Tel: + 381 11 30 73 900, Fax: + 381 11 30 73 973
E-mail: office@inpharm.rs
Kako deluje
Ulje račića(Krill oil)
- Štiti kardiovaskularni sistem i održava normalne vrednosti holesterola
Koenzim Q10
- Štiti ćelije od oksidativnog oštećenja
- Reguliše stvaranje energije u celom organizmu
- Savetuje se kao dodatak statinima i beta-bokatorima koji snižavaju nivo CoQ10
- Smanjuje mogućnost pojave zamora u mišićima
- Savetuje se kod pacijenata sa kardiomiopatijom i srčanom slabošću
Polikozanoli
- Dovodi do redukcije ukupnog i "lošeg" LDL holesterola
- Povećava dobar HDL holesterol
- Inhibira abnormalnu agregaciju trombocita
- U kliničkim studijama dokazana podjednaka efikasnost sa statinima
Reference
1.Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, Berge K, Vik H, Pedersen JI. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46(1):37-46. 2. Buena R, El Farrah K, Deutsch L, Evaluation of the Effects of Neptune Krill Oil on the Clinical Course of Hyperlipidemia. Alter Med Rev. 2004;9(4):420-428. 3. Pashkow F, Watumull D, Campbell C: Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008,101(10A):58D-68D. 4. Ghirlanda, G; Oradei, A; Manto, A; Lippa, S; Uccioli, L; Caputo, S; Greco, AV; Littarru, GP (1993). "Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study". The Journal of Clinical Pharmacology 33 (3): 226–9. 5. Caso G. et al. (2007, May). Effect of coenzyme q10 on myopathic symptom s in patients treated with statins. The American Journal of Cardiology. 15;99(10):1409-12. Retrieved December 3rd, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/17493470. 6. Rosenfeldt F. et al. (2003). Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 18(1-4):91-100. Retrieved December 3rd, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/14695924. 7. Pons P., Rodriguez M., Robaina C., et al. (1994): Effects of succesive dose increases of policosanol on lipid profile of patients with type-II hypercholesterolemia and tolerability to treatment. J. Clin. Pharmacol. Res. 14:27-33. 8. Canetti M., Morera M., Illnait J., et al. (1995): A two year study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia. Intern. J. Clin. Pharmacol. Res. 15:159-165. 9. Dalmer Laboratory. Policosanol vs lovastatin: Comparative study on efficacy, safety and tolerability in the treatment of type II hypercholesterolemia. Data on file. 10. Benitez M., Romero C., Mas R., et al. (1997): A comparative study of policosanol vs pravastatin in patients with type-II hypercholesterolemia. Curr. Ther. Res. 58:859-67. 11. Ortensi G., Gladstein J., Vail H. and Tesone P.A. (1997): A comparativc study of policosanol vs. simvastatin in elderly patients with hypercholesterolemia. Curr. Ther. Res. 58:390-401. 12. Arruzazabala M. L., Carbajal D., Mas R. and Valdes S. (1997): Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 36(4):293-7.